A series of novel analogs of water soluble pterostilbene amino acid bearing carbonates were synthesized, which show activities in treating a non-alcoholic fatty liver disease and a nonalcoholic steatohepatitis (NASH).

LSD derivative compounds and polymorphs thereof, methods for their synthesis, compositions and treatment of diseases and disorders are described herein, the compounds having the structure of Formula I:

##STR00001##

including pharmaceutically acceptable salts, hydrates, solvates, tautomers, enantiomers, diastereomers, racemates, polymorphs or combinations thereof; wherein: R.sup.1 to R.sup.14 are each independently selected from H, or a substituted or unsubstituted hydrocarbon group and X is selected from a halo group.

This disclosure relates to novel detergents for use in various procedures including, for example, nucleic acid amplification reactions such as polymerase chain reaction (PCR). Methods for preparing the modified detergents are also described.

This disclosure relates to novel detergents for use in various procedures including, for example, nucleic acid amplification reactions such as polymerase chain reaction (PCR). Methods for preparing the modified detergents are also described.

The present embodiment provides a compound represented by the formula (1):
Q-CHR.sub.2  (1)
(Q is a nitrogen-containing aliphatic group containing two or more tertiary nitrogens but no oxygen, and R is an aliphatic group containing a biodegradable group). From the compound in combination with other lipids such as a lipid capable of reducing aggregation, lipid particles can be formed. Further, the compound can be used for a pharmaceutical composition to deliver an activator into cells.

Compounds are provided having the following structure (I) or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein G.sup.1, G.sup.1′, G.sup.2, G.sup.2′, G.sup.3, L.sup.1, L.sup.1′, L.sup.2, L.sup.2′, X, X′, Y and Y′ are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided. ##STR00001##

Compounds are provided having the following structure (I) or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein X, Y, L.sup.1, L.sup.2, L.sup.3, G.sup.1, G.sup.2 and G.sup.3 are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided. ##STR00001##

The present disclosure describes compounds of Formula (I) or a pharmaceutically acceptable salt thereof:

##STR00001##

wherein: R.sup.1 and R.sup.2 are each independently (CH.sub.3(CH.sub.2).sub.m).sub.2CH—, (CH.sub.3(CH.sub.2).sub.m)(CH.sub.3(CH.sub.2).sub.m-1)CH, (CH.sub.3(CH.sub.2).sub.m)(CH.sub.3(CH.sub.2).sub.m-2)CH, (CH.sub.3(CH.sub.2).sub.m).sub.2CHCH.sub.2—, or (CH.sub.3(CH.sub.2).sub.m)(CH.sub.3(CH.sub.2).sub.m-1)CHCH.sub.2—, wherein m is 4-11; L.sup.1 and L.sup.2 are each independently absent, a linear C.sub.1-5 alkylene, or (CH.sub.2).sub.p—O—(CH.sub.2).sub.q, wherein p and q are each independently 1-3; R.sup.3 is a linear C.sub.2-5 alkylene optionally substituted with one or two methyl groups; R.sup.4 and R.sup.5 are each independently H or C.sub.1-6 alkyl; X is O or S; and n is 0-2.

The present disclosure describes compounds of Formula (I) or a pharmaceutically acceptable salt thereof:

##STR00001##

wherein: R.sup.1 and R.sup.2 are each independently (CH.sub.3(CH.sub.2).sub.m).sub.2CH—, (CH.sub.3(CH.sub.2).sub.m)(CH.sub.3(CH.sub.2).sub.m-1)CH, (CH.sub.3(CH.sub.2).sub.m)(CH.sub.3(CH.sub.2).sub.m-2)CH, (CH.sub.3(CH.sub.2).sub.m).sub.2CHCH.sub.2—, or (CH.sub.3(CH.sub.2).sub.m)(CH.sub.3(CH.sub.2).sub.m-1)CHCH.sub.2—, wherein m is 4-11; L.sup.1 and L.sup.2 are each independently absent, a linear C.sub.1-5 alkylene, or (CH.sub.2).sub.p—O—(CH.sub.2).sub.q, wherein p and q are each independently 1-3; R.sup.3 is a linear C.sub.2-5 alkylene optionally substituted with one or two methyl groups; R.sup.4 and R.sup.5 are each independently H or C.sub.1-6 alkyl; X is O or S; and n is 0-2.

The present invention relates to metformin amino acid compounds (SLNs), pharmaceutical compositions thereof, and methods of using them for the treatment of hyperglycemia, diabetes, and Type 2 diabetes. The compounds can be synthesized using the processes disclosed herein.